Prohost Letter #400 NEAR-­TERM INVESTING The Prohost Letter #399 Part 3 has Promised to Des

There is nothing wrong with Nektar Therapeutics (NKTR). The stock is temporarily underperforming as traders are …

Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the …

EXELIXIS APPROVED PRODUCTS 1. CABOMETYX™(CABOZANTINIB) For Exelixis (EXEL) the two approved oncology products cabozantinib and cobimetinib …

News about investigational drugs, which are expected to make big differences in the lives of people …

The FDA approval of Sarepta’s (SRPT) Duchenne muscular dystrophy (DMD) product, Exondys 51 (eteplirsen), surprised many …

Another gene editing firm, CRISPR Therapeutics decided to become publicly traded. On Friday, the private firm …

Xoma’s (XOMA) webcast and conference call scheduled for September 15, 2016, at 1:30 p.m. PDT (4:30 …

At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good …

Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors …